Company intelligence / Profile preview

Remedy Plan Therapeutics

Gaithersburg, Maryland, United Statesremedyplan.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Currently conducting a Phase 1 clinical trial of RPT1G (first-in-class hyperbolic NAMPT inhibitor) in adult healthy volunteers. The trial will evaluate safety, pharmacokinetics, and pharmacodynamics in preparation for upcoming oncology trials in AML and MDS patients. Dosing was initiated in November 2024.

Therapeutic areas: OncologyImmunologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

RPT1G

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Remedy Plan Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Remedy Plan Therapeutics.

Explore the full profile